Host-Based Th2 Cell Therapy for Prolongation of Cardiac Allograft Viability by Amarnath S et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is made available under the Creative Commons CC0 public domain dedication. 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Amarnath S, Chen H, Foley JE, Costanzo CM, Solomon MA, Sennesh JD, 
Fowler DH. Host-Based Th2 Cell Therapy for Prolongation of Cardiac Allograft 
Viability. PLoS ONE 2011, 6(4), e18885. 
 
 
Copyright: 
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, 
transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made 
available under the Creative Commons CC0 public domain dedication. 
DOI link to article: 
http://dx.doi.org/10.1371/journal.pone.0018885  
Date deposited:   
23/10/2015 
  
Host-Based Th2 Cell Therapy for Prolongation of Cardiac
Allograft Viability
Shoba Amarnath1*., Hao Chen2,3., Jason E. Foley1, Carliann M. Costanzo1, Joel D. Sennesh4, Michael A.
Solomon2,5, Daniel H. Fowler1
1 Experimental Transplantation and Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America, 2Critical
Care Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland, United States of America, 3Department of Cardiac Surgery, Huadong Hospital, Fudan
University, Shanghai, China, 4Department of Pathology, Inova Fairfax Hospital, Fairfax, Virginia, United States of America, 5Cardiovascular and Pulmonary Branch,
National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, Maryland, United States of America
Abstract
Donor T cell transfusion, which is a long-standing approach to prevent allograft rejection, operates indirectly by alteration of
host T cell immunity. We therefore hypothesized that adoptive transfer of immune regulatory host Th2 cells would
represent a novel intervention to enhance cardiac allograft survival. Using a well-described rat cardiac transplant model, we
first developed a method for ex vivo manufacture of rat host-type Th2 cells in rapamycin, with subsequent injection of such
Th2.R cells prior to class I and class II disparate cardiac allografting. Second, we determined whether Th2.R cell transfer
polarized host immunity towards a Th2 phenotype. And third, we evaluated whether Th2.R cell therapy prolonged allograft
viability when used alone or in combination with a short-course of cyclosporine (CSA) therapy. We found that host-type
Th2.R cell therapy prior to cardiac allografting: (1) reduced the frequency of activated T cells in secondary lymphoid organs;
(2) shifted post-transplant cytokines towards a Th2 phenotype; and (3) prolonged allograft viability when used in
combination with short-course CSA therapy. These results provide further support for the rationale to use ‘‘direct’’ host T
cell therapy for prolongation of allograft viability as an alternative to ‘‘indirect’’ therapy mediated by donor T cell infusion.
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Introduction
Clinical interventions to prolong cardiac allograft survival have
relied primarily on long-term post-transplant administration of
calcineurin inhibitors such as cyclosporine A (CSA) for suppression
of host T cells that mediate rejection [1] [reviewed in [2]]. However,
long-term calcineurin inhibitor therapy is typically only partially
effective and the T cell immune deficiency predisposes to life
threatening infection and malignancy [reviewed in [3]]. As such,
new approaches in transplantation seek to limit patient exposure to
calcineurin inhibitors and to promote immune tolerance through
either pharmacologic or cellular interventions [reviewed in [4,5]].
‘‘Donor specific tolerance’’ was observed when recipients of T
cell-containing, third-party blood transfusion prior to clinical
organ transplantation were found to have a reduced incidence of
graft rejection [6,7,8]. Recent animal model experiments have
demonstrated that the reduction in graft rejection through donor
T cell infusion occurs ‘‘indirectly’’ through modulation of host T
cells [9,10]. Most recently, in a murine model of transplantation
tolerance, donor regulatory T (Treg) cells contained within
transferred blood products were found to induce naive host T
cells to adopt a Treg phenotype [11].
As such, various T cell transfer methods that result in the
modulation of host T cell populations represent a general approach
to prolong allograft survival. Recently, we have shown that donor T
cells polarized into a Th2 phenotype modulate host T cells towards
a Th2 phenotype, thereby preventing graft rejection in a murine
model of hematopoietic stem cell transplantation [12,13]. Based on
this background, we now project that host Th2 cell adoptive
transfer may represent a ‘‘direct’’ pathway to prolong solid organ
allograft viability. Host T cell therapy would be particularly useful
for cardiac allograft recipients due to the lack of cadaveric donor T
cells. In addition, rat cardiac allograft rejection has been
characterized as a Th1-type process [14], and therefore predictably
amenable to Th2 cell therapy, which we have shown to be capable
of modulating Th1-type transplantation responses [12]. Towards
this aim, we tested our hypothesis in a well-characterized rat
cardiac allograft transplantation model.
In murine models of graft rejection [12] and graft-versus-host
disease [15], we found that adoptive transfer of Th2 cells that were
manufactured ex vivo in rapamycin (‘‘Th2.R cells’’) were more
effective than control Th2 cells; the increased in vivo efficacy of
Th2.R cells is likely due to their rapamycin-induced anti-apoptotic
phenotype, which permits prolonged in vivo T cell persistence
[13]. In light of these data, we hypothesized that adoptive cell
therapy using host-type Th2.R cells may represent a novel
approach to modulate host immunity towards a Th2 phenotype
for prolongation of solid organ transplant survival.
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Results
Ex vivo manufacture of rat CD4+ Th2 cells with or without
rapamycin
There are no reports in the literature pertaining to the ex vivo
manufacture of rat Th2 cells in the presence of rapamycin; as
such, we first evaluated if rat CD4+ T cells could be polarized to a
Th2 phenotype during rapamycin exposure. In previous experi-
ments evaluating Th2 cell therapy in the context of murine
allogeneic bone marrow transplantation, we identified an effective
strategy whereby cytokine polarization occurred ex vivo in a
polyclonal manner, with subsequent acquisition of allosensitization
in vivo [16]; as such, for these studies, we performed cytokine
polarization in the context of polyclonal co-stimulation. Co-
stimulation and IL-4 priming in the presence or absence of
rapamycin resulted in T cells expressing a Th2 phenotype, as
defined by minimal IFN-c secretion (Fig. 1a, panel i; Fig. 1b,
panels i, ii, iii) and high levels of IL-4 secretion (Fig. 1a, panel ii;
Fig. 1b, panel iv, v, vi). Relative to control Th2 cells (‘‘Th2’’),
rapamycin treated Th2 cells (‘‘Th2.R’’) secreted higher amounts of
IL-4 (P,0.05 for supernatant assay in Fig. 1a; p = 0.03 for i.c. flow
cytometry assay in Fig. 1b). Control Th2 cells and Th2.R cells
each had minimal expression of the Treg transcription factor,
Foxp3 (Fig. 1c; percent CD4+Foxp3+ expression, mean 6 SEM,
Th2 vs. Th2.R: 2.060.5 vs. 0.560.6). As such, ex vivo rapamycin
enhanced host T cell Th2 polarity without promoting a Treg
phenotype.
Th2.R cell therapy combined with CSA therapy reduces T
cell activation during allograft challenge and augments
post-transplant Th2 polarity
Expanded host-type Th2.R cells were infused intravenously into
recipient (host-type) rats following cardiac transplantation surgery
at day 0. Cohorts received the allograft either alone (‘‘allograft’’) or
in combination with: CSA for 28 days (CSA 28); CSA for 18 days
(CSA 18); Th2.R cells; or Th2.R cells plus (CSA 18). At the final
day 28 post-transplant endpoint, recipients in the rejection control
cohort that did not receive CSA or Th2.R cells had low
frequencies of CD4+CD25+Foxp3+ T cells (Fig. 2a top panels)
and had high frequencies of CD4+CD25+Foxp32 activated
effector T cells (Fig. 2a, bottom left panel) and CD8+CD25+
Foxp32 activated effector T cells (Fig. 2a, bottom right panel) in
the spleen, inguinal lymph nodes, and mesenteric lymph nodes. By
comparison, recipients of daily subcutaneous CSA therapy had
undetectable levels of activated effector CD4+ and CD8+ T cells.
Statistical analyses were performed, with comparison of each
experimental cohort to the rejection control cohort. Relative to
rejection controls, recipients of a short-course of CSA alone,
Th2.R cells alone, or the combination of short-course CSA plus
Th2.R cells had decreased frequencies of effector CD4+ and CD8+
T cells; as such, both CSA and Th2.R cell infusion reduced in vivo
host T cell activation during allograft challenge.
Next, we evaluated the cytokine profile of the various cohorts at
day 28 post-transplant; post-transplant T cell cytokine production
was induced after polyclonal stimulation using co-stimulation
(Fig. 2b) and by syngeneic and allogeneic antigen-presenting-cell
(APC) stimulation to determine allospecific cytokine secretion
(Fig. 2c). Upon co-stimulation and allogeneic APC activation,
spleen and lymphoid cells isolated from recipients of short-course
CSA or the combination of short-course CSA plus Th2.R cells had
increased secretion of IL-4 relative to spleen and lymphoid cells
isolated from recipients of either continuous daily CSA therapy or
Th2.R cell therapy alone (Fig. 2b and 2c, respectively); the
mechanism(s) whereby short-course CSA consistently increased
post-transplant IL-4 secretion capacity is not clear and was not
addressed in our experiments. The rejection control cohort
secreted low levels of IL-4. As such, whereas daily CSA therapy
suppressed the host Th2 response, short-course CSA and Th2 cell
transfer promoted Th2 immunity. Furthermore, infusion of Th2.R
cells in the context of short-course CSA therapy reduced post-
transplant T cell capacity to secrete IFN-c in both a polyclonal
and an allospecific manner (Fig. 2b and 2c, respectively).
Evaluation of Th2.R cell therapy timing and rapamycin
co-administration
Further experiments were performed in host-type BN rats to
optimize Th2.R cell therapy. We hypothesized that infusion of
host Th2.R cells one or two weeks prior to the allogeneic
transplant might induce more marked host skewing towards a Th2
state, thereby enhancing a Th2.R cell protection against graft
rejection. In lieu with our prior finding that murine Th2.R cells
were relatively resistant to in vivo rapamycin drug therapy [17],
we also hypothesized that pre-transplant co-administration of
rapamycin might further augment the host Th2 state. Indeed, at
day 7 after host Th2.R cell infusion, there was a dramatic increase
in host capacity to secrete IL-4 (Fig. 3a); however, co-administra-
tion of rapamycin actually abrogated this host Th2 shift. Of note,
host immunity was not significantly polarized at day 14 after
Th2.R cell infusion; as such, further experiments focused on an
anti-rejection strategy incorporating Th2.R cell infusion at day27
pre-transplant. Seven days after treatment with CD4+ Th2.R cells,
no significant increase in Foxp3+ T cells was observed (Fig. 3b).
Both host CD4+ and CD8+ T cells were enriched for IL-4
secretion capacity (Fig. 3c; Representative flow plot panel i gated
on CD8+ T cells and ii gated on CD4+ T cells; summary iii and iv);
as such, similar to our previous work in murine models, the
adoptive transfer of highly purified rat CD4+ Th2.R cells resulted
in the transfer of Th2 immunity to other host T cell populations.
Of note, Th2.R cell induction of host CD4+ and CD8+ T cell IL-4
secretion was inhibited by rapamycin co-administration. Th2
skewing was confirmed by the ability of the host CD8+ T cells to
secrete IL4. Furthermore, seven days after host Th2.R cell
infusion, we observed a marked decrease in host CD4+ T cell
capacity for IFN-c secretion (Fig. 3c; v). Interestingly, rapamycin
drug therapy did not reduce CD4+ T cell IFN-c secretion in a
statistically significant manner. In addition, Th2.R cells or
rapamycin did not significantly alter IFN-c secretion capacity
within host CD8+ T cells (Fig. 3c; vi). Since rapamycin was not
permissive for Th2 polarization in our system, further experiments
tested Th2.R cell therapy in the setting of CSA rather than
rapamycin drug therapy.
Th2.R cell therapy combined with short-course CSA
therapy prolongs cardiac allograft viability
We next evaluated host-based Th2.R cell therapy in a stringent,
28-day model of allograft rejection that utilized CSA for only the
initial 10 days post-transplant. At day 28 post-transplant, as
anticipated, recipients of daily CSA (through day 28 post-
transplant) had reduced CD8+ T cell activation in the spleen,
inguinal lymph nodes, and mesenteric lymph nodes relative to
recipients of short-course CSA (Fig. 4a; top panels). Remarkably,
host Th2.R cell infusion plus short-course CSA also reduced CD8+
T cell activation at these tissue sites to levels comparable with daily
CSA therapy; in general, this CD8+ T cell inhibition occurred
whether Th2.R cells were administered at day 27, day 0, or day
27 plus day 0. However, Th2.R cell infusion without short-course
CSA did not inhibit CD8+ T cell activation. In marked contrast to
Host Th2 Cell Conditioning
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Figure 1. Characterization of rat Th2 cells. CD4+ T cells were isolated and expanded using anti-CD3 and anti-CD28 co-stimulation in the
presence of rhIL-2, rrIL-4, and rhIL-7 either with rapamycin (‘‘Th2.R’’) or without rapamycin (‘‘Th2’’) for 3 days. (a) Expanded Th2 and Th2.R cells were
subjected to repeat co-stimulation, and the 24 h supernatant was tested for cytokine content using multiplex bead array. (b) After repeat co-
stimulation, Th2 and Th2.R cells were evaluated for intra-cellular expression of IFN-c and IL-4 by flow cytometry. (c) On day 3, cells were harvested and
intra-cellular flow cytometry was performed to evaluate Foxp3 transcription factor expression. Results are a summary of n = 10 cultures.
doi:10.1371/journal.pone.0018885.g001
Host Th2 Cell Conditioning
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Figure 2. Host Th2.R cell infusion prolongs cardiac allograft survival. Rat allogeneic cardiac transplants was performed and assigned to one
of five treatment cohorts, including: no drug and no cell therapy (‘‘rejection control’’); 28-day daily cyclosporine A therapy [‘‘CSA(28);’’ engraftment
control]; Th2.R adoptive cell therapy alone on the day of transplant [‘‘Th2.R(d0)’’]; 18-day, short-course CSA therapy alone [‘‘CSA(18)’’; experimental
control]; or a combination of short-course CSA plus Th2.R cell therapy [‘‘CSA(18)+Th2.R(d0)’’]. (a) At day 28 post-transplant, recipients were euthanized
and spleen, inguinal lymph nodes, and mesenteric lymph nodes were harvested. The frequency of activated CD4+ and CD8+ T cells in each cohort at
Host Th2 Cell Conditioning
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these CD8+ T cell results, CSA therapy and/or Th2.R cell therapy
did not significantly alter CD4+ T cell activation (Fig. 4a; bottom
panels); it is possible that the substantial CD4+ T cell activation in
Th2.R cell recipients reflects activation of the adoptively
transferred Th2.R cells.
Next, we evaluated the in vivo cytokine profile at day 28 post-
transplant. Spleen cells from recipients of daily CSA therapy
secreted very low levels of IFN-c in a polyclonal manner (Fig. 4b)
or in an allospecific manner (Fig. 4d). In contrast, spleen cells from
recipients of either short-course CSA alone or Th2.R cells alone
had increased polyclonal and allospecific secretion of IFN-c. Of
note, multiple infusions of Th2.R cells (both day 27 and day 0)
prior to transplantation resulted in a decrease in IFN-c secretion
relative to recipients of a single dose Th2.R cells. Recipients of
short-course CSA plus Th2.R cells (independent to Th2.R cell
timing) had decreased polyclonal and allospecific IFN-c secretion
relative to recipients of short-course CSA alone. Relative to
recipient of short-course CSA alone, recipients of short-course
CSA plus Th2.R cell infusion had an increase in allospecific IL-4
secretion (Fig. 4e); this increase in allospecific IL-4 secretion was
observed in each of the three cohorts to receive Th2.R cells.
Interestingly, limited differences was noted in IL-4 secretion
between cohorts on polyclonal stimulation (Fig. 4c).
Furthermore, at day 28 post-transplant, we tested for the
presence of activated T cells within the cardiac allografts. As
anticipated, recipients of short-course CSA alone had a high
frequency of activated CD4+ and CD8+ T cells infiltrating the
graft (Fig. 4f); by comparison, recipients of daily CSA had minimal
evidence of intra-cardiac activated T cells. Relative to recipients of
short-course CSA alone, recipients of Th2.R cell therapy in
combination with short-course CSA therapy had reduced
frequencies of intra-cardiac activated CD8+ T cells. Interestingly,
Th2.R cell therapy reduction in the frequency of intra-graft
activated CD4+ T cells was modest relative to CD8+ T cells;
however, marked reductions of intra-graft activated CD4+ T cells
were observed in recipients of Th2.R cells on day 0 of transplant.
Most importantly, intra-cardiac T cells from Th2.R cell recipients
had greatly reduced capacity to secrete IFN-c in an allospecific
manner relative to recipients of short-course CSA (Fig. 4g).
As anticipated, the control group that received short-course
CSA universally had non-viable cardiac allografts by day 28 post-
transplant (Fig. 4h); recipients of Th2.R cells alone also universally
had nonviable allografts. Administration of daily CSA predictably
increased the incidence of clinical graft viability (graft viability
frequency, 85%). Remarkably, recipients of short-course CSA
combined with Th2.R cells at day 0, day27, or day27 plus day 0
were also generally protected from graft failure (graft viability
frequencies: 86%, 100%, 100%, respectively; Table 1). Haema-
toxylin and eosin staining obtained at day 28 post-transplant
demonstrated that recipients of short-course CSA, who had poor
allograft viability, had severe myocardial necrosis and a dense
mononuclear cell infiltration (Fig. 5a). In contrast, recipients of
short-course CSA combined with host Th2.R cell therapy had
minimal myocardial necrosis in the setting of substantial
mononuclear cell infiltration; importantly, recipients of short-
course CSA plus Th2 cells on day 0 of transplant had a statistically
significant reduction in rejection by standard histology criteria
(Fig. 5b). Of note, recipients of Th2 cells at day 27 plus day 0 of
transplant or day 27 of transplant, who had 100% graft viability,
did not have reduced histology scores.
Discussion
Utilizing a well-characterized experimental rat cardiac trans-
plantation model, we have shown that allograft viability can be
prolonged by direct modulation of host immunity via adoptive T
cell therapy using rapamycin-generated Th2-type cells. These data
add to the growing body of information relating to cellular
approaches to rejection prevention, and squarely places an
emphasis upon use of host T cell populations as an alternative
to indirect modulation of host immunity via third-party donor cell
infusions. Importantly, as a step towards potential clinical
translation, we have determined that host Th2-type cell adoptive
transfer is efficacious when used in combination with calcineurin
inhibitor therapy, which remains the standard of care therapy.
Reports more than 30 years ago determined that donor-specific
[18] or third-party [19] transfusions reduced solid organ
transplantation rejection through a phenomenon termed donor-
specific-tolerance. However, further clinical advances with respect
to use of adoptive cell therapy for rejection abrogation did not
ensue, in part because the mechanism(s) underlying transfusion-
induced tolerance have not been fully characterized and in part
because adoptive cell therapy is only now becoming a burgeoning
translational medical approach [20]. It has long been proposed
that modulation of host T cell immunity might be harnessed to
promote graft tolerance, including an early study of ‘‘host T cell
vaccination’’ prior to experimental transplantation [21]; however,
further investigations into host derived T cell based engraftment
strategies have been limited. Extensive mechanistic data exists on
donor specific tolerance [11], [14] where adoptive transfer of ex
vivo generated host Treg cells prevents allograft rejection [22,23].
Although focus has been placed upon host Tregs for cellular
induction of transplantation tolerance [reviewed in [24,25]], other
host T cell populations such as CD42CD82 ‘‘double-negative’’ T
cells have been shown to facilitate engraftment [26]. In this
context, our current results using host-type, rapamycin-generated
Th2 cells indicate that a diversity of functionally-defined host T
cell subsets represent candidate populations to prevent solid organ
graft rejection.
The current study is the first to demonstrate that the adoptive
transfer of Th2 polarized host T cells represents a candidate
approach to prolong cardiac allograft viability. Although enthu-
siasm for the potential role of Th2 responses for the regulation of
Th1-mediated solid organ rejection has waned with the resurgence
of Treg cell research [reviewed in [27]], several previous studies
have supported a beneficial role of Th2 cells in cardiac
transplantation models, including: evidence that type II cytokines
help promote ‘infectious tolerance’ [28]; modulation of the Th1/
Th2 balance via ICAM/LFA blockade [14]; and Treg cell up-
regulation of IL-4 and Th2 responses during infectious tolerance
[29]. In our studies, the phenotype of the ex vivo, rapamycin-
generated host T cell population was consistent with an effector
Th2 phenotype, as indicated by prolific secretion of IL-4, a high
precursor frequency of cells capable of IL-4 secretion, and minimal
expression of the Treg cell transcription factor, FoxP3. These
results stand somewhat in contrast to other ex vivo results that
described rapamycin to promote Treg cell differentiation [30], but
each organ site was then determined by flow cytometry (percent of CD4+ or CD8+ T cells that co-expressed CD25 in the absence of Foxp3 expression;
results are mean 6 SEM of 3 evaluated per cohort; *, indicates p#0.05; **, indicates p#0.005). Cells harvested at day 28 post-transplant were co-
stimulated (b) or allo-stimulated (c & d), and the 24 h supernatants were tested for cytokine content by multiplex assay.
doi:10.1371/journal.pone.0018885.g002
Host Th2 Cell Conditioning
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are consistent with our murine results that have identified a
capacity to generate either effector Th1 and Th2 populations in
rapamycin depending upon polarizing cytokine exposure [17,31].
Most importantly, the adoptively transferred T cells mediated a
Th2-type response in vivo, as evidenced by: increased post-transfer
IL-4 secretion; reduced post-transfer IFN-c secretion; and minimal
induction of Foxp3-expressing T cells. We also observed that
recipients of the CD4+ Th2.R cells were enriched for post-
transplant CD8+ T cell capacity for IL-4 secretion capacity; this
result indicates that the post-transplant Th2 polarization induced
through Th2.R cell infusion could be attributable not only to the
infused Th2 cell product but also to the transfer of Th2 polarity to
endogenous T cells. Similar to our previous observations in murine
bone marrow transplant models that utilizing donor-derived
Th2.R cells [15,32], we also observed that host adoptive Th2
cell therapy significantly reduced the number of post-transplant
CD8+ T cells in secondary lymphoid organs; given the major role
for host CD8+ T cells in mediating cardiac allograft rejection
[33,34], we speculate that Th2-mediated control of CD8+ T cell
immunity may account in part for allograft survival effect we
observed in this model. It is interesting to note that Th2.R cell
infusion alone did not achieve post-transplant skewing towards a
Th2 phenotype, whereas Th2.R cell infusion plus short-course
CSA consistently yielded increased post-transplant IL-4 and
reduced post-transplant IFN-c. We speculate that CSA therapy
is limiting the expansion of the host Th1-type rejection response,
thereby allowing expansion of the infused Th2 cells; in the absence
of CSA, the Th2 cells may be inhibited by a predominant Th1
response.
Our results stand somewhat in contrast to previous studies that
found Tc2 cells [35] or IL-4 [36] to be detrimental to graft
survival. We speculate that our use of purified CD4+ T cells that
secreted high levels of IL-4 may help account for the positive
results we achieved with a type II cytokine strategy; further
experiments will be required to clarify specific molecular
mechanisms that account for the Th2.R cell therapeutic effect.
It should be mentioned that our model utilizes a relatively short
recipient follow-up for assessment of allograft viability, and as
such, the effect of the Th2 cell strategy on long term allograft
viability would require further study [37]. We observed that both
the long-term immune suppression cohort and the short-course
suppression plus Th2.R cohort each had prolonged allograft
viability; therefore, from these experiments, we can not conclude
that one strategy is advantageous relative to the other. Rather, we
conclude that short-course suppression plus infusion of a T cell
modulation population such as the host Th2.R cells may represent
an alternative to long-term immune suppression. Determination of
the relative risks and benefits of each approach would require
further comparative studies in additional models.
It is important to point out that, in spite of the increase in
cardiac viability in Th2.R cell recipients, such recipients did not
have a reduction in the rejection score by standard histology
criteria. It should be noted that the rejection score is based heavily
on mononuclear cell infiltration; because we found that Th2.R cell
recipients had relatively dense intra-cardiac T cell infiltration by
cells that did not secrete allospecific IFN-c, it is possible that in the
context of interventions such as host-type Th2.R cell transfer,
cardiac infiltration by mononuclear cells alone may not accurately
predict rejection. Finally, it should also be noted that we did not
assess the impact of Th2.R cell infusion on alloantibody formation,
which can play an important role as a mediator of kidney allograft
rejection [reviewed in [38]].
Infusion of host-type Th2.R cells one week pre-transplant
optimally promoted host Th2-type immunity at the time of
transplant and preserved allograft viability in 100% of recipients.
Since the Th2.R cell product was generated in high-dose
rapamycin, we predicted that the Th2.R cells may be relatively
resistant to the effects of in vivo rapamycin, thereby further
promoting an in vivo Th2 shift; however, to the contrary, co-
administration of rapamycin drug therapy abrogated the ability of
Th2.R cells to polarize host immunity towards a Th2 phenotype.
In our previous murine studies, we did observe that ex vivo
rapamycin resistance does not necessarily confer resistance to
rapamycin in vivo [17]; such observations may be due to
rapamycin blockade of non-T cell pathways in vivo, such as
antigen-presenting-cell populations [39] that may help drive T cell
expansion in vivo. Furthermore, we also determined that
administration of rapamycin did not increase Foxp3+ regulatory
T cells in vivo. In contrast to these results using in vivo rapamycin,
we found that cyclosporine therapy was permissive for the immune
modulatory effect generated through Th2 cell therapy. As such,
although experimental models indicate that rapamycin has more
tolerance-induction properties relative to cyclosporine therapy
[40,41,42], our data indicate that calcineurin inhibitor therapy
may be preferentially utilized in the setting of polarized Th2.R cell
therapy for solid organ allografting. It is also important to note
that infusion of Th2.R cells on the same day as cardiac allografting
was sufficient to prolong allograft survival; this lack of requirement
for pre-infusion of Th2 cells would be advantageous for clinical
translation because of the unpredictability of cardiac allograft
availability.
In conclusion, the adoptive transfer of ex vivo generated,
rapamycin-resistant host Th2-type cells represents an effective new
approach to the prolongation of cardiac allograft viability. These
data support the current momentum in the field to develop
adoptive cell therapies for tolerance induction in a calcineurin-
inhibitor sparing manner, and suggests that functionally-defined
and cytokine-polarized effector T cells, as well as Treg cells, may
contribute to the future armamentarium to protect against solid
organ allograft rejection.
Materials and Methods
Animal care
The experiments were performed as part of a protocol
approved by the Animal Care and Use Committee (ACUC) of
the Clinical Center of the National Institutes of Health (NIH;
Animal study protocol approval number CCM 06-02). Inbred
male brown Norway (BN) and dark agouti (DA) rats, weighing
200–250 g, were purchased from Charles River Laboratories
(Wilmington, MA) and maintained under pathogen free
conditions.
Figure 3. Evaluation of Th2.R cell timing and rapamycin co-administration. Host-type BN rats received an intravenous infusion of isogeneic
Th2.R cells either at day 27 or day 214 prior to host euthanasia at ‘‘day 0’’, with subsequent immune evaluation; Th2 cell therapy was administered
either alone or in combination with in vivo rapamycin therapy. (a) Harvested spleen, inguinal lymph node, and mesenteric lymph node cells were
harvested and subjected to co-stimulation; resultant 24 h supernatants were then tested for cytokine content by Multiplex assay. (b) % Foxp3
expression was measured using IC flow on splenocytes at day7 (c) After co-stimulation, CD4+ and CD8+ T cells from recipients in each cohort were
evaluated by intra-cellular flow cytometry for IFN-c and IL-4 production. * indicates P,0.05; n = 5 per cohort.
doi:10.1371/journal.pone.0018885.g003
Host Th2 Cell Conditioning
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Antibodies and reagents
RPMI media, rapamycin, and sodium pyruvate was obtained
from Sigma (St.Louis, MO) and FCS was from Gem Cell (West
Sacramento, CA). CD4 microbeads were from Miltenyi Biotec
(Auburn, CA). Goat anti-rat Ig G was from Qiagen (Valencia,
CA). Anti-CD3, anti-CD28 coated tosyl-activated magnetic beads
were manufactured as previously described [43]. Recombinant
human (rh) IL-2, (rh) IL-7 and (rr) IL-4 were from PeproTech
(Rocky Hill, NJ). Penicillin-streptomycin-glutamine, nonessential
amino acid and N-acetyl-L-cysteine was obtained from Invitrogen
Figure 4. Th2.R cell therapy plus cyclosporine reduces host T cell activation, induces a host Th2 phenotype, and reduces intra-
cardiac allospecific T cells. Rat allogeneic cardiac transplants were performed and assigned to one of eight treatment cohorts, including; 28-day
daily cyclosporine A therapy [‘‘CSA(28)’’; engraftment control]; Th2.R adoptive cell therapy alone (‘‘Th2.R’’) at day 0 (D0), day-7 (D-7) or both (D-7+D0);
10-day, short-course CSA therapy alone [‘‘CSA(10);’’ experimental control]; or a combination of short-course CSA plus Th2.R cell therapy
[‘‘CSA(10)+Th2.R’’] at day 0 (D0), day-7 (D-7) or both (D-7+D0). (a) At day 28 post-transplant, transplant recipients were euthanized and splenocytes
were harvested. The frequency of activated CD4+ and CD8+ T cells in each cohort at each organ site was then determined by flow cytometry (percent
of CD4+ or CD8+ T cells that co-expressed CD25 in the absence of Foxp3 expression; results are mean 6 SEM of 5 or 7 evaluated per cohort;
*, indicates p,0.05). Splenocytes were harvested and subjected to either co-stimulation (b & c) or syngeneic and allogeneic APC stimulation (d & e;
allospecific cytokine secretion is shown); resultant 24 h supernatants were then tested for cytokine content by Multiplex assay. (f) The frequency of
activated CD4+ and CD8+ T cells in harvested cardiac tissue was determined by flow cytometry (percent of CD4+ or CD8+ T cells that co-expressed
CD25 in the absence of Foxp3 expression; results are mean 6 SEM of 7 evaluated per cohort; *, indicates p,0.05). (g) Intracardiac T cells were
subjected to stimulation with allogeneic dendritic cells; resultant 24 h supernatants were then tested for cytokine content by Multiplex assay. (h)
Survival of cardiac allografts between various cohorts is shown.
doi:10.1371/journal.pone.0018885.g004
Table 1. Summary of experimental design.
Experimental Design for data in Figure #2
Treatment Cohorts (n) Cardiac Allograft1
CSA Drug Therapy
(Total Days)2
Immunotherapy
Th2.R (Day administered)3
1. n = 3 (Rejection Control) Y N N
2. n = 3 (Treatment Control) Y Y (28) N
3. n = 3 (Sub-optimal Drug Therapy) Y Y (18) N
4. n = 3 (Immunotherapy) Y N Y (0)
5. n = 3 (Immunotherapy) Y Y (18) Y (0)
Experimental Design for data in Figure #3
Treatment Cohorts (n) Cardiac Allograft
Rapamycin Drug Therapy
(Total Days prior to transplant)4
Immunotherapy
Th2.R (Day administered)
1(Experimental Control), n = 5 N CMC (7) N
2(Experimental Control), n = 5 N RAPA (7) N
3(Immunotherapy), n = 5 N CMC (7) Y (27)
4(Immunotherapy), n = 5 N RAPA (7) Y (27)
5(Experimental Control), n = 5 N CMC (14) N
6(Experimental Control), n = 5 N RAPA (14) N
7(Immunotherapy), n = 5 N CMC (14) Y (214)
8(Immunotherapy), n = 5 N RAPA (14) Y (214)
Experimental Design for data in Figure #4&5
Treatment Cohorts Cardiac Allograft
CSA Drug Therapy
(Total Days)
Immunotherapy
Th2.R (Day administered)
1(Rejection Control), n = 7 Y Y (10) N
2(Treatment Control), n = 7 Y Y (28) N
3(Immunotherapy), n = 7 Y N Y (0)
4(Immunotherapy), n = 5 Y N Y (27)
5(Immunotherapy), n = 4 Y N Y (0 & 27)
6(Immunotherapy), n = 5 Y Y (10) Y (0)
7(Immunotherapy), n = 7 Y Y (10) Y (27)
8(Immunotherapy), n = 7 Y Y (10) Y (0 & 27)
1Y = yes, N = no; DA donor hearts transplanted into BN recipient rats.
2Cyclosporine (CSA) administered subcutaneously (10 mg/kg/day).
3Th2.R = Th2 cells were generated from host BN CD4+ T cells.
4Rapamycin (Rapa) administered i.p (1.5 mg/kg/day); CMC= carboxymethylcellulose.
doi:10.1371/journal.pone.0018885.t001
Host Th2 Cell Conditioning
PLoS ONE | www.plosone.org 9 April 2011 | Volume 6 | Issue 4 | e18885
Life Technologies (Carlsbad, CA). All antibodies (unless otherwise
stated) were purchased from BD Biosciences (BD; San Diego, CA);
anti-rat Foxp3 APC was from eBioscience (San Diego, CA).
Luminex kits for detection of rat IL-2, IL-4, IFN-c and IL-10 were
from Bio-Rad (Hercules, CA). Cyclosporine A (CSA or Sandim-
muneH) was from Novartis (Hanover, NJ).
T cell subset isolation and ex vivo culture of Th2.R cells
Spleens were harvested from host type BN rats, RBC lysed and
B cells were depleted (goat anti-rat IgG beads); CD4 T cells were
enriched using Miltenyi CD4 microbeads as per manufacturer’s
instructions. Total CD4+ T cells were cultured in polystyrene
tissue culture flasks (Corning; Lowell, MA). Cells were activated by
anti-CD3 (clone:G4.18), anti-CD28 (clone: JJ316) co-stimulation
(bead:cell ratio, 3:1) and cultured in RPMI media containing 10%
FCS, 16 Sodium pyruvate, 16 non-essential amino acids, b-ME
(561025 M), 16streptomycin-penicillin and glutamine. Cytokines
(rh) IL-2 (100 IU/ml), (rh) IL-7 (20 ng/ml), (rr) IL-4 (10000 IU/
ml) and rapamycin (10 mM) were added to the culture at day 0.
Cultures were started at 1.56106 cells/ml, and (rh) IL-2 was again
added at day 2. Cultures were harvested on day 3 for phenotyping
and adoptive transfer experiments.
Heterotropic cardiac transplantation
Brown-Norway (BN) rats served as recipient and Dark Agouti
(DA) rats served as allograft cardiac donor. Allogeneic cardiac
Figure 5. Th2.R cell therapy plus cyclosporine prolongs cardiac allograft survival. Allograft recipients were monitored for cardiac viability
through the 28-day post-transplant period of observation. Rejection and engraftment control cohorts received a 10-day short-course of cyclosporine
A [‘‘CSA(10]’’ or a daily 28-day course of ‘‘CSA [CSA(28)’’]. Other cohorts received either no cyclosporine A or short-course CSA(10) in combination with
Th2.R cell therapy at day 27 [‘‘Th2.R(D-7)’’ or ‘‘CSA(10)+Th2.R(D-7)’’], day 0 [‘‘Th2.R(D0)’’ or ‘‘CSA(10)+Th2.R(D0)’’], or day 27 plus day 0 [‘‘Th2.R(D-
7+D0)’’ or ‘‘CSA(10)+Th2.R(D-7+DO)’’]. (a) Hematoxylin and eosin staining was performed at day 28 post-transplant. Left panels show a representative
example of severe allograft rejection in recipients of short-course CSA(10) alone (characterized by diffuse inflammation and necrosis); right panels
show a representative example of relatively preserved myocardial cell structure and reduced mononuclear cell infiltration in recipients of short-course
CSA(10) therapy plus Th2.R cell therapy. (b) Cumulative histology score between various cohorts is shown. I = isograft, A =Allograft; IHC
score = Immunohistochemistry score.
doi:10.1371/journal.pone.0018885.g005
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transplantations were performed using a modified version of the
heterotopic cardiac transplantation model reported by Yokoyama
et al [44]. As previously described [45], preparation of the donor
heart for transplantation entailed ligation of pulmonary vessels,
superior vena cava and inferior vena cava (IVC), creation of an
atrial septal defect, and disruption of the tricuspid valve leaflets.
The donor ascending aorta was anastamosed to the recipient
abdominal aorta and the donor right atrium was anastamosed to
the recipient IVC. Upon re-establishment of blood flow, all
transplanted hearts resumed spontaneous contractions, had
coordinated atrioventricular activity, and were free of gross
surgical injury at the time of closure. The transplanted animals
were subjected to various treatments with CSA (0, 10, 18, or 28
day regimen), rapamycin, and adoptive transfer of 16107 Th2.R
cells per injection (at day 0 of transplant and/or day 27 pre-
transplant), as summarized in Table 2. Survival of cardiac grafts
was evaluated by daily palpation; cessation of heartbeat was
interpreted as lack of viability. Specimens were processed for
histopathology using hematoxylin and eosin staining [46].
Flow cytometry
T cells were washed with PBS supplemented with 0.1% BSA
and 0.01% azide, and stained using anti-: CD4 PE-cy5 (clone ox-
35), CD8 APC (clone ox-8), CD3 biotin (clone g.18), Streptavidin
PE-cy7 and CD25 PE (clone ox-39). For intra-cellular (IC) flow
cytometry, fixation and permeabilization buffer was utilized
(eBioscience); Intracellular flow cytometry was performed with
combinations of anti-: IFN-c FITC (clone DB-1; Biolegend, San
Diego, CA), IL-4 PE (clone ox-81), CD4 PE-Cy7 and Foxp3
Pacific Blue (clone FJK-16s; eBioscience). Cells were analyzed
using a BD Biosciences LSR II (San Jose, CA) equipped with 488,
633, 405 and 355 nm lasers and thirteen detectors. Data was
acquire using DiVa ver. 5.1 (BD Biosciences), and analyzed using
FlowJo ver. 8.8 (Treestar Software, Ashland, WA).
Allogeneic mixed lymphocyte reaction (MLR)
Bone marrow DC were generated from DA and BN rats, RBC
lysed and cultured in RPMI media with 5% FCS, (rr) GM-CSF
(50 ng/ml), and (rr) IL-4 (20 ng/ml) for 5 days. Bacterial LPS
(1 mg/ml; Sigma) was added to the culture for 24 hrs and DC were
harvested. The DC from syngeneic and allogeneic hosts were
utilized to stimulate spleen cells for measuring allo-specific
responses.
Cytokine analysis using multibead array
The expanded Th2 cells were harvested at day 3 and extensively
washed with media prior to restimulation with anti-CD3 and anti-
CD28. Supernatants were collected 24 hr post-stimulation and
analyzed for cytokines using the Biorad Multiplex bead array.
Single cell suspensions of spleen (16106/ml), inguinal lymph nodes
(16106/ml), and mesenteric lymph nodes (16106/ml) were
obtained from rats post-transplant and stimulated with anti-
CD3, anti-CD28 coated beads followed by incubation at 37uC for
24 hrs. The supernatants were harvested and Th1/Th2 cytokine
profile was measured using a Biorad multiplex bead array. In some
experiments, T cells were stimulated with BN or DA dendritic cells
(DC) (spleen cell to DC ratio, 10:1) for 24 h. Allogeneic cytokine
secretion was subtracted out of syngeneic cytokine secretion and is
presented as allo-specific responses.
Statistical analysis
Flow cytometry and cytokine data were analyzed using student’s
2-tailed t tests. Comparison values of p,0.05 were considered statis-
tically significant. Survival was determined using Kaplan Meier test.
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